Equities Analysts Offer Predictions for VVOS Q3 Earnings

Vivos Therapeutics, Inc. (NASDAQ:VVOS) – Analysts at HC Wainwright issued their Q3 2025 earnings estimates for Vivos Therapeutics in a research note issued to investors on Monday, November 17th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of ($0.55) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Vivos Therapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for Vivos Therapeutics’ Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.00) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.24) EPS and FY2026 earnings at ($1.19) EPS.

A number of other research analysts also recently commented on the stock. Ascendiant Capital Markets raised their target price on shares of Vivos Therapeutics from $6.20 to $6.50 and gave the company a “buy” rating in a research report on Tuesday, September 9th. Zacks Research downgraded shares of Vivos Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, October 31st. Wall Street Zen downgraded shares of Vivos Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $5.25.

Vivos Therapeutics Stock Performance

VVOS stock opened at $2.47 on Wednesday. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.05 and a quick ratio of 1.05. The business has a 50-day moving average price of $2.97 and a 200 day moving average price of $3.52. The company has a market capitalization of $18.54 million, a P/E ratio of -1.47 and a beta of 6.88. Vivos Therapeutics has a 1-year low of $1.98 and a 1-year high of $7.95.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings results on Tuesday, August 19th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.16). The firm had revenue of $3.82 million for the quarter, compared to the consensus estimate of $3.37 million. Vivos Therapeutics had a negative return on equity of 232.76% and a negative net margin of 99.49%.

Institutional Investors Weigh In On Vivos Therapeutics

Institutional investors have recently bought and sold shares of the company. Connective Capital Management LLC purchased a new position in Vivos Therapeutics in the third quarter worth $620,000. B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics during the 2nd quarter worth $220,000. Finally, XTX Topco Ltd purchased a new position in Vivos Therapeutics during the 2nd quarter worth $65,000. 26.35% of the stock is currently owned by institutional investors and hedge funds.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.